| Old Articles: <Older 6221-6230 Newer> |
|---|
 |
InternetNews
March 1, 2010 |
Major Tech Firms Back Online Health Care Cisco, Dell, Google, IBM and Microsoft all make news at the major health care show.   |
Chemistry World
February 26, 2010
Sarah Houlton |
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
February 26, 2010
Brian Orelli |
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. |
The Motley Fool
February 26, 2010
Brian Orelli |
Political Theater: More Entertaining Than Helpful Health-care reform, like health-care stocks, remains still stuck in limbo. |
The Motley Fool
February 26, 2010
Tim Hanson |
This Stock Costs Less Than a Sandwich And that makes it a pretty good deal. Female Health Co., a maker of female condoms is still on the AMEX and trading for less than $3 per share. |
BusinessWeek
February 25, 2010
Weintraub & Tirrell |
Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed. |
The Motley Fool
February 25, 2010
Brian Orelli |
Transplanting Future Revenue Bristol-Myers Squibb waits for experts to decide the fate of its kidney cancer drug. |
The Motley Fool
February 25, 2010
Brian Orelli |
13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer. |
| <Older 6221-6230 Newer> Return to current articles. |
